Cargando…

A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol

BACKGROUND: Cluster immunotherapy represents an interesting alternative to conventional up-dosing schedules because it allows achieving the maintenance dose within a shorter time interval. In this study, the efficacy and safety of cluster immunotherapy with a high polymerized allergen extract of a g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klimek, L, Uhlig, J, Mösges, R, Rettig, K, Pfaar, O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238814/ https://www.ncbi.nlm.nih.gov/pubmed/25130503 http://dx.doi.org/10.1111/all.12513

Ejemplares similares

A high‐dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio
por: Pfaar, Oliver, et al.
Publicado: (2023)

Ultra‐short‐course booster is effective in recurrent grass pollen‐induced allergic rhinoconjunctivitis
por: Pfaar, O., et al.
Publicado: (2017)

Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study
por: Shah-Hosseini, Kija, et al.
Publicado: (2017)

Update about Oralair® as a treatment for grass pollen allergic rhinitis
por: Klimek, L., et al.
Publicado: (2022)

Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial
por: Mösges, R., et al.
Publicado: (2018)

7 Comparison of Efficacy and Safety of a Dipigmented Polymerized Allergen Extract of Grass and Birch with Placebo in Patients With Type-1 Allergic Rhinoconjunctivitis
por: Sager, Angelika, et al.
Publicado: (2012)

Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study
por: Pfaar, Oliver, et al.
Publicado: (2015)

Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial
por: Hylander, Terese, et al.
Publicado: (2016)

A randomized, double‐blind, placebo‐controlled, dose‐finding trial with Lolium perenne peptide immunotherapy
por: Mösges, R., et al.
Publicado: (2017)

A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT‐birch pollen extract for the treatment of allergic rhinitis: results of a phase II study
por: Pfaar, O., et al.
Publicado: (2015)

An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial
por: Chaker, A. M., et al.
Publicado: (2016)

Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE)
por: Slovick, Anna, et al.
Publicado: (2013)

Detection of genuine grass pollen sensitization in children by skin testing with a recombinant grass pollen hybrid
por: Douladiris, Nikolaos, et al.
Publicado: (2018)

PD14 - Non-interventional 2-year study of sublingual immunotherapy in children and adolescents with allergic rhinoconjunctivitis caused by grass pollen
por: Karagiannis, Efstrathios, et al.
Publicado: (2014)

5-grass-pollen SLIT effectiveness in seasonal allergic rhinitis: Impact of sensitization to subtropical grass pollen
por: van Nunen, Sheryl A., et al.
Publicado: (2022)

Economic Evaluation of 5-Grass Pollen Tablets Versus Placebo in the Treatment of Allergic Rhinitis in Adults
por: Ruggeri, Matteo, et al.
Publicado: (2013)

Aerobiological Monitoring and Metabarcoding of Grass Pollen
por: Krinitsina, Anastasia A., et al.
Publicado: (2023)

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32
por: Niederberger, Verena, et al.
Publicado: (2018)

Oral administration of Lactobacillus paracasei NCC 2461 for the modulation of grass pollen allergic rhinitis: a randomized, placebo-controlled study during the pollen season
por: Nembrini, Chiara, et al.
Publicado: (2015)

P85 - Asthmatic children and adolescents treated in daily medical practice – results from a 2-year sublingual allergen immunotherapy (AIT) study with grass pollen tablets
por: Karagiannis, Efstrathios, et al.
Publicado: (2014)

A double-blind, placebo-controlled trial of the efficacy and safety of two doses of azelastine hydrochloride in perennial allergic rhinitis
por: Bousquet, Jean, et al.
Publicado: (2023)

Treatment of grass pollen allergy: focus on a standardized grass allergen extract – Grazax(®)
por: Calderón, Moisés, et al.
Publicado: (2008)

A Group-1 Grass Pollen Allergen Influences the Outcome of Pollen Competition in Maize
por: Valdivia, Elene R., et al.
Publicado: (2007)

Exposure to grass pollen – but not birch pollen – affects lung function in Swedish children
por: Gruzieva, O., et al.
Publicado: (2015)

Discrimination of grass pollen of different species by FTIR spectroscopy of individual pollen grains
por: Diehn, Sabrina, et al.
Publicado: (2020)

Nonpharmacological measures to prevent allergic symptoms in pollen allergy: A critical review
por: Bergmann, Karl-Christian, et al.
Publicado: (2021)

Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
por: Dellinger, Ryan W., et al.
Publicado: (2017)

Personalized Pollen Monitoring and Symptom Scores: A Feasibility Study in Grass Pollen Allergic Patients
por: de Weger, Letty A., et al.
Publicado: (2021)

Relative potency in SPT of solution and tablet SLIT allergen extracts of Timothy grass pollen from 2 European manufacturers compared to a US reference extract
por: Larenas-Linnemann, Désirée, et al.
Publicado: (2015)

Sensitization to timothy grass pollen allergenic molecules in children
por: Scaparrotta, Alessandra, et al.
Publicado: (2013)

Differences in grass pollen allergen exposure across Australia
por: Beggs, Paul J., et al.
Publicado: (2015)

Sensitization Profiles of Timothy Grass Pollen in Northern China
por: Xu, Yingyang, et al.
Publicado: (2021)

Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing()
por: Zielen, S., et al.
Publicado: (2019)

161 Efficacy and Safety of 300IR 5-Grass Pollen Sublingual Allergen Immunotherapy Tablets in us Adults With Grass-Pollen Allergic Rhinoconjunctivitis
por: Cox, Linda, et al.
Publicado: (2012)

Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial
por: Klimek, Ludger, et al.
Publicado: (2015)

Supplementation of Dihomo-γ-Linolenic Acid for Pollen-Induced Allergic Symptoms in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial
por: Yokoi, Kaori, et al.
Publicado: (2023)

Dose-Response of Paraxanthine on Cognitive Function: A Double Blind, Placebo Controlled, Crossover Trial
por: Xing, Dante, et al.
Publicado: (2021)

Safe and effective delivery of supplemental iron to healthy older adults: The double-blind, randomized, placebo-controlled trial protocol of the Safe Iron Study
por: Lewis, Erin D., et al.
Publicado: (2021)

Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study
por: Worm, Margitta, et al.
Publicado: (2014)

Author Correction: Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
por: Dellinger, Ryan W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_41k9s4q0teeudu7i89diphu93a